menu
    • menu
    [{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SHINE Technologies \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SHINE Technologies \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"WARF Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"177-Lu ART-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHINE Technologies \/ WARF Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SHINE Technologies \/ WARF Therapeutics"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHINE Technologies \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"1","companyTruncated":"SHINE Technologies \/ Fidelity Management & Research Company"}]

    Find Clinical Drug Pipeline Developments & Deals by SHINE Technologies

    Menu

    SHINE Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    SHINE Technologies

    U.S.A arrow
    German Wound Congress
    Not Confirmed

    SHINE Technologies

    U.S.A arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 177-Lu ART-101

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : WARF Therapeutics

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    SHINE Partners with UW-Madison, WARF on Kidney and Prostate Cancer Therapies

    Details : The collaboration aims to create promising new treatments for kidney and prostate cancers. ART-101, a novel prostate cancer treatment developed using SHINE's Ilumira, demonstrates superior efficacy.

    Product Name : 177-Lu ART-101

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 17, 2024

    Lead Product(s) : 177-Lu ART-101

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : WARF Therapeutics

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    SHINE Technologies

    U.S.A arrow
    German Wound Congress
    Not Confirmed

    SHINE Technologies

    U.S.A arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 177-Lu Rosopatamab Tetraxetan

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Telix Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Telix and SHINE Partner for Lutetium-177 Supply

    Details : SHINE will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the ...

    Product Name : TLX591

    Product Type : Radiolabelled Compounds

    Upfront Cash : Undisclosed

    November 02, 2022

    Lead Product(s) : 177-Lu Rosopatamab Tetraxetan

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Telix Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    SHINE Technologies

    U.S.A arrow
    German Wound Congress
    Not Confirmed

    SHINE Technologies

    U.S.A arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 177-Lu

    Therapeutic Area : Oncology

    Study Phase : Undisclosed

    Sponsor : Fidelity Management & Research Company

    Deal Size : $80.0 million

    Deal Type : Series C Financing

    DEALS_DEV arrow-down

    Shine Closes $80-Million Series C Financing Supported by Fidelity Management and Research Company Llc

    Details : Fuding will support SHINE's continued effort to make strong progress in their work to commercialize molybdenum-99, an essential diagnostic isotope, and lutetium-177, a therapeutic isotope that is showing great promise for the treatment of cancer.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 09, 2020

    Lead Product(s) : 177-Lu

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Sponsor : Fidelity Management & Research Company

    Deal Size : $80.0 million

    Deal Type : Series C Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth